Premark Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Angel
- Latest Deal Amount
-
$957K
- Investors
-
1
Premark Pharma General Information
Description
Developer of novel therapeutic drugs designed to treat ophthalmic diseases. The company specializes in developing topical treatments for inflammatory diseases of the skin, eye, mucosae, and mucocutaneous surfaces, enabling doctors to cure patients suffering from unmet conditions.
Contact Information
Website
www.premarkpharma.comCorporate Office
- Christoph Merian-Ring 11
- 4153 Reinach
- Switzerland
Corporate Office
- Christoph Merian-Ring 11
- 4153 Reinach
- Switzerland
Premark Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 09-Jun-2022 | $957K | Completed | Clinical Trials - Phase 3 | ||
| 1. Seed Round | 07-Mar-2019 | Completed | Clinical Trials - Phase 3 |
Premark Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Premark Pharma Patents
Premark Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4687895-A1 | Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale | Pending | 06-Apr-2023 | ||
| WO-2024209038-A1 | Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale | Inactive | 06-Apr-2023 | ||
| EP-3972583-B1 | Pimecrolimus ointment for treating moderate to severe blepharitis | Active | 21-May-2019 | ||
| EP-3972583-C0 | Pimecrolimus ointment for treating moderate to severe blepharitis | Active | 21-May-2019 | ||
| ES-3067708-T3 | Pimecrolimus ointment for treating moderate to severe blepharitis | Active | 21-May-2019 | A61K31/436 |
Premark Pharma Signals
Premark Pharma Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority |
Premark Pharma FAQs
-
When was Premark Pharma founded?
Premark Pharma was founded in 2018.
-
Where is Premark Pharma headquartered?
Premark Pharma is headquartered in Reinach, Switzerland.
-
What is the size of Premark Pharma?
Premark Pharma has 2 total employees.
-
What industry is Premark Pharma in?
Premark Pharma’s primary industry is Drug Discovery.
-
Is Premark Pharma a private or public company?
Premark Pharma is a Private company.
-
What is the current valuation of Premark Pharma?
The current valuation of Premark Pharma is .
-
What is Premark Pharma’s current revenue?
The current revenue for Premark Pharma is .
-
How much funding has Premark Pharma raised over time?
Premark Pharma has raised $957K.
-
Who are Premark Pharma’s investors?
has invested in Premark Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process